- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Merck’s (NYSE:MRK) odanacatib osteoporosis drug has significantly strengthened hip and spine bone mineral density in a phase two trial of post-menopausal women, who had prior to the test taken the firm’s Fosamax treatment. A spokesperson remarked “Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they (already) received.”
Eli Lilly and Company’s (NYSE:LLY) ramucirumab drug for gastric cancer has met its main goal of improving overall survival in a Phase III study. The treatment at the same time increased survival without the cancer becoming worse.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Shares of Amedisys (NASDAQ:AMED) plunge on word that the firm renews its agreement to supply home health services to Humana (NYSE:HUM), and then reported that revenue from the arrangement will be half the yearly range of between $65 million and $70 million that it’s brought in so far. The agreement will bigin to impact revenues in the fourth quarter.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.